• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Relypsa

edit

Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa’s lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

Milestones

edit

• 
  Relypsa received $70M in Series B funding. (9/13/10)
  Posted 9/14/10 at 5:39pm via finsmes.com
• 
  Relypsa received $33M in Series A funding. (10/29/07)
  Posted 3/11/09 at 9:52am via venturebeat.com

Videos

Screenshots

edit

Traffic Analytics

Compete

Sources

1. Amgen, Relypsa and the art of the biotech-spinout-startup-restart (venturebeat.com) [edit]
2. Relypsa Raises $70M in Series B Financing (finsmes.com) [edit]